Colonrectal Cancer
5
0
0
2
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
8 treatments under study, led by Ct Perfusion
Research Leaders
8 sponsors active, led by Stanford University
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
40.0%
2 terminated out of 5 trials
50.0%
-36.6% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Compassion-Based Rehabilitation Needs Assessment Following Colorectal Cancer Surgery
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
Research Network
Common Treatments
- Ct Perfusion1
- Bevacizumab1
- Capecitabine1
- Compassionate Access Targeted Therapy1
- Frozen Tumor Specimens1
Active Sponsors
- Stanford University3
- Siemens Corporation, Corporate Technology1
- GE Healthcare1
- Caring for Carcinoid Foundation1
- Esbjerg Hospital - University Hospital of Southern Denmark1
Top Investigators
Stanford University
Stanford University
Stanford University
Stanford University
Stanford University
Related Conditions
- Colonrectal Cancer Rectal Cancer2
- Hepatobiliary Cancers2
- Anal Colon And Rectal Cancers2
- Colonrectal Cancer Colon Cancer2
- Colorectal Neoplasms2